Structured evidence table for Nicotinamide Cognition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Nicotinamide Cognition Randomized Trial | In parallel, epidemiological evidence has consistently linked specific dietary patterns, such as the Mediterranean and MIND diets, to a reduced risk of cognitive decline and AD []. | 2 | Kumari Ankita (2026) | Dietary Bioactives in Alzheimer’s Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies |
| Nicotinamide Cognition Randomized Trial | These changes progress to reduced brain volume and are responsible for the memory loss associated with AD []. | 2 | Kumari Ankita (2026) | Dietary Bioactives in Alzheimer’s Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies |
| Nicotinamide Cognition Randomized Trial | This definition aligns with the Office of Dietary Supplements (NIH, Bethesda, MD, USA) framework, which characterizes bioactives as food or supplement constituents, excluding essential nutrients that influence cellular activities, metabolic pathways, or disease risk []. | 2 | Kumari Ankita (2026) | Dietary Bioactives in Alzheimer’s Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies |
| Nicotinamide Cognition Randomized Trial | 1 2 The prevalence of Alzheimer’s disease (AD) is projected to escalate in line with rising life expectancies across various nations. | 2 | Kumari Ankita (2026) | Dietary Bioactives in Alzheimer’s Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies |
| Nicotinamide Cognition Randomized Trial | In the NR-NR group, NAD+ levels increased by 2.6- to 3.1-fold after 5-10 weeks of supplementation, respectively, and remained elevated at 20 weeks. | 2 | Wu CY (2025) | Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. |
| Nicotinamide Cognition Randomized Trial | Interpretation In long-COVID, NR increased NAD+ within 5 weeks but did not significantly improve cognition, fatigue, sleep, or mood vs. | 2 | Wu CY (2025) | Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. |
| Nicotinamide Cognition Randomized Trial | Background Long-COVID often involves cognitive difficulties, immune dysregulation, and mitochondrial dysfunction. | 2 | Wu CY (2025) | Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. |
| Nicotinamide Cognition Randomized Trial | Studies suggest nicotinamide adenine dinucleotide (NAD+) precursors like nicotinamide riboside (NR) may reduce inflammation and support mitochondrial and neurological function. | 2 | Wu CY (2025) | Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. |
Source documents